RecruitingPhase 3NCT06832410
An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of VX-880 in Subjects With Type 1 Diabetes With a Kidney Transplant
Sponsor
Vertex Pharmaceuticals Incorporated
Enrollment
10 participants
Start Date
Mar 31, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria3
- Clinical history of T1D with greater than or equal to (≥)5 years of insulin dependence
- Taking a stable immunosuppression regimen of tacrolimus and mycophenolate mofetil, mycophenolate sodium, or sirolimus for at least 4 weeks
- Consistent use of continuous glucose monitor (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study
Exclusion Criteria2
- Prior islet cell transplant, organ transplant (other than kidney transplant), or cell therapy, except prior pancreatic graft that failed within the first 4 weeks
- Participants had \>1 kidney transplant procedure
Interventions
BIOLOGICALBiological/Vaccine
Infused into the hepatic portal vein.
Locations(7)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06832410
Related Trials
Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients
NCT063246044 locations
EMPoWER Study - Strengths-based Behavioral Intervention for Youth With Type 1 Diabetes
NCT060148791 location
Intervention for Children With Type 1 Diabetes Targeting Gut Microbes
NCT061987251 location
Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 Diabetes Using Automated Insulin Delivery
NCT072121791 location
A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
NCT0706157411 locations